GlassScriptPhysician profile
Heather Cannon
NPI 1801082409
$1,659.67
in general payments reported to CMS, 2019-2025
18 companies · $99.18 in 2025
The $99.18 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $239 · 2021: $341 · 2022: $284 · 2023: $302 · 2024: $120 · 2025: $99.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $426.97 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $256.29 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.80 | 2022-2023 | |
| Lilly USA, LLC | $177.91 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $138.96 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.62 | 2019-2021 | |
| Pfizer INC. | $66.74 | 2019-2025 | |
| Allergan, INC. | $53.49 | 2019-2020 | |
| Abbott Laboratories | $52.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $34.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.09 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $29.28 | 2022-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $22.98 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.01 | 2022 | |
| Genentech USA, INC. | $17.45 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2019 | |
| Mckesson Medical-Surgical, INC. | $13.85 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.